Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Bayer AG
How BAYRY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-09 | Sunharbo (asundexian) | PDUFA Date Approved | PDUFA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Darolutamide Small MoleculesMarketedNCT04464226 | Cancer | Approved | ACTIVE NOT_RECRUITING | 774 | Jun 26, 2028 | ||||||
| Darolutamide Small MoleculesNCT05794906 | Biochemically Recurrent Prostate Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,013 | Mar 29, 2030 | ||||||
| Darolutamide Small MoleculesNot countedNCT05676203 | Metastatic Hormone-sensitive Prostate Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 727 | Dec 1, 2026 | ||||||
| Darolutamide Small MoleculesNCT07450599 | High-risk Localized Prostate Cancer | Phase 2 | RECRUITING | 250 | Oct 15, 2030 | ||||||
| Darolutamide Small MoleculesMarketedNCT07244341 | Metastatic Castration-resistant Prostate Cancer | Approved | RECRUITING | 120 | Nov 30, 2029 | ||||||
| Darolutamide Small MoleculesMarketedNCT05826509 | Prostate Cancer | Approved | ACTIVE NOT_RECRUITING | 2,129 | Feb 1, 2031 | ||||||
| Finerenone Small MoleculesMarketedNCT05196035 | Chronic Kidney Disease | Approved | ACTIVE NOT_RECRUITING | 7,246 | May 10, 2027 | ||||||
| Finerenone Small MoleculesNCT07192952 | Left Ventricular Systolic Dysfunction | Phase 3 | RECRUITING | 228 | Dec 30, 2030 | ||||||
| regorafenib Small MoleculesNCT06246643 | Solid Malignant Tumors | Phase 2 | ACTIVE NOT_RECRUITING | 13 | Apr 27, 2028 | ||||||
| VVD-133214 Small MoleculesNCT07811193 | Colorectal Adenocarcinoma | Phase 2 | RECRUITING | 140 | Dec 31, 2030 | ||||||
| OpCT-001 BiologicsNCT06789445 | Primary Photoreceptor Disease | Phase 1/2 | RECRUITING | 54 | Oct 1, 2030 | ||||||
| BAY 3713372 Small MoleculesNCT06914128 | MTAP-deleted Solid Tumors | Phase 1/2 | RECRUITING | 450 | Jun 18, 2029 | ||||||
| BAY 3670549 Small MoleculesNCT07625215 | Atrial Fibrillation | Phase 2 | RECRUITING | 360 | May 16, 2030 | ||||||
| Elinzanetant Small MoleculesNCT05587296 | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 474 | Jun 5, 2028 | ||||||
| Elinzanetant Small MoleculesNCT07762287 | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women | Phase 1 | RECRUITING | 100 | Jan 22, 2027 | ||||||
| Nurandociguat Small MoleculesNCT07431294 | Stable Coronary Artery Disease | Phase 1 | NOT YET_RECRUITING | 36 | May 7, 2027 | ||||||
| BAY 3771249 Small MoleculesNCT07535112 | Advanced/Metastatic Colorectal Adenocarcinoma | Phase 1 | RECRUITING | 130 | Jul 9, 2030 | ||||||
| bemdaneprocel Cell TherapiesNCT06944522 | Parkinsons Disease (PD) | Phase 3 | RECRUITING | 102 | Aug 1, 2034 | ||||||
| Sevabertinib Small MoleculesMarketedNCT06452277 | Advanced Non-small Cell Lung Cancer, HER2 Mutation | Approved | RECRUITING | 444 | Jun 27, 2029 | ||||||
| Sevabertinib Small MoleculesNCT06760819 | Advanced Solid Tumors | Phase 2 | RECRUITING | 111 | Oct 26, 2029 | ||||||
| BAY 3389934 Small MoleculesNCT06854640 | Sepsis | Phase 1 | RECRUITING | 36 | Jan 17, 2027 | ||||||
| AB-1005 Gene TherapiesNCT06285643 | Parkinson Disease | Phase 2 | ACTIVE NOT_RECRUITING | 85 | Aug 31, 2028 | ||||||
| BAY1213790 BiologicsCompletedNCT04523220 | End-stage Renal Disease | Phase 2 | COMPLETED | 704 | May 30, 2022 | ||||||
| Fesomersen RNA-Based TherapiesCompletedNCT04534114 | End Stage Renal Disease Requiring Hemodialysis | Phase 2 | COMPLETED | 307 | May 12, 2022 | ||||||
| Darolutamide Small MoleculesMarketedNCT02200614 | Prostate Cancer Non-Metastatic | Approved | COMPLETED | 1,509 | Jun 14, 2021 |
Readouts, endpoints and source filings for every BAYRY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BAYRY for Q3 2026. | ||||
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How BAYRY ranks across every disease it competes in